AACR 2024 – Astra plays up PARP1 inhibition
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
Merck KGaA takes a punt on Inspirna’s novel approach
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
Merck KGaA takes another shot at PARP1
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
